Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789591 | 0.91 | HRH3 (0.56) | HRH3HRH1CYP2D6MLNRKDM2B | |
| SCHEMBL5459050 | 0.87 | HRH3 (0.47) | HRH3HRH1CYP2D6MLNRKDM2B | |
| SCHEMBL5457102 | 0.82 | HRH3 (0.73) | HRH3HRH1CYP2D6KDM2B | |
| SCHEMBL5670668 | 0.80 | HDAC4 (0.39) | HRH3CYP2D6 | |
| SCHEMBL5458210 | 0.77 | HRH3 (0.63) | HRH3HRH1CYP2D6 | |
| Potassium Ion SCHEMBL1787639 | 0.77 | HRH3 (0.49) | HRH3CYP2D6MLNRKDM2B | |
| SCHEMBL12608382 | 0.77 | HRH3 (0.51) | HRH3HRH1CYP2D6MLNRKDM2B | |
| SCHEMBL5660240 | 0.77 | HRH3 (0.72) | HRH3HRH1CYP2D6MLNRKDM2B | |
| SCHEMBL1786584 | 0.76 | HPGD (0.46) | HRH3CYP2D6MLNR | |
| SCHEMBL5465499 | 0.76 | ESR2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885HRH1 101/4885CYP2D6 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.